NCT06942572: A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 57 planned
- Started
- 11 Feb 2025
- Primary completion
- 31 Oct 2028
- Arms
- Phase 1 Dose Escalation - Low Dose, Phase 1 Dose Escalation - Medium Dose, Phase 1 Dose Escalation - High Dose, Phase 2 Dose Expansion: Dose 1 from Phase 1 Randomised Arm, Phase 2 Dose Expansion: Dose 2 from Phase 1 Randomised Arm
- Results
- None posted
- 11 Feb 2025: Trial started
- 24 Apr 2025: Trial registered